Thomas Balle

Professor Thomas Balle is a Professor in the Sydney Pharmacy School, Faculty of Medicine and Health, at the University of Sydney, where he serves as Honours Coordinator. He holds an MSc Eng and a PhD. Before joining the University of Sydney in 2012, he was an Associate Professor at the University of Copenhagen, Denmark, where he led the X-ray Crystallography platform at the Faculty of Health and Medical Sciences. His transition to Sydney marked a continuation of his expertise in advanced structural and computational approaches to pharmaceutical research.

Professor Balle's research centers on medicinal chemistry, computational chemistry, and structural biology, with a particular emphasis on ligand-gated ion channels. Key areas include nicotinic acetylcholine receptors (nAChRs), GABAA receptors, P2X7 receptors, and NMDA receptors. He utilizes techniques such as homology modeling, molecular docking, pharmacophore modeling, and molecular dynamics simulations to explore structure-function relationships and develop novel drugs for neurological and psychotropic conditions. His contributions extend to computer-aided drug design for CNS disorders, including investigations into receptor modulation by anaesthetics, analgesics, and potential antiviral agents targeting GABAA receptors. Professor Balle has supervised numerous PhD and Honours projects, contributing to education in drug discovery and pharmacy.

With over 111 peer-reviewed publications, his work has garnered more than 2,956 citations according to Google Scholar, reflecting substantial impact in pharmacology and neuroscience. Select publications include: 'A Pharmacophore for Drugs Targeting the α4α4 Binding Site of the (α4)3(β2)2 Nicotinic Acetylcholine Receptor' (2025); 'Deep learning structural insights into heterotrimeric alternatively spliced P2X7 receptors' (2023); 'The Anti-Nociceptive Effects of Nicotine in Humans: A Systematic Review and Meta-Analysis' (2023); 'GABAA receptors as targets for anaesthetics and analgesics and promising candidates to help treat coronavirus infections: A mini-review' (2022); 'Alternatively Spliced Isoforms of the P2X7 Receptor: Structure, Function and Disease Associations' (2022); and earlier works such as 'Engineered α4β2 nicotinic acetylcholine receptors as models for pharmacological studies of central nervous system receptors' (2015) and 'Structural and functional studies of the modulator NS9283 reveal agonist-like mechanism of action at α4β2 nicotinic acetylcholine receptors' (2014). His research has been presented at international symposia, including on ion channel drug discovery.

Professional Email: thomas.balle@sydney.edu.au